Advances in Pharmaceutics / 2015 / Article / Tab 4

Research Article

Formulation, Optimization, and Characterization of Repaglinide Loaded Nanocrystal for Diabetes Therapy

Table 4

Measurement of % entrapment efficiency, PDI, particle size, In vitro drug release, and zeta potential.

Sr. numberDependent variable
BatchPDIIn vitro drug release study (%)Particle size (nm) Zeta potential (mv)
(Mean ± SD), = 3(Mean ± SD), = 3 (Mean ± SD), = 3(Mean ± SD), = 3

1NC 10.510 ± 0.1255.38 ± 1.25386.7 ± 10.88−22.9 ± 0.48
2NC 20.267 ± 0.0669.08 ± 0.64213.5 ± 8.68−23.4 ± 1.22
3NC30.248 ± 0.0480.58 ± 1.71187 ± 5.09−29.4 ± 1.00
4NC 40.665 ± 0.0859.64 ± 1.1743.5 ± 12.16−16.4 ± 2.43
5NC 50.6 ± 0.165.33 ± 1.41543.4 ± 9.66−25.8 ± 0.52
6NC 60.570 ± 0.0578.26 ± 2.08443.7 ± 7.56−28 ± 2.56
7NC 70.478 ± 0.0732.88 ± 0.98619 ± 10.74−5.69 ± 0.89
8NC 80.355 ± 0.0544.69 ± 1.21509.4 ± 11.56−7.67 ± 0.78
9NC 90.540 ± 0.1452.71 ± 1.29751 ± 14.13−1.19 ± 1.55